People
Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.
Training the next generation of scientists is a key for the future of the biotech industry and Regeneron Pharmaceuticals is taking a lead in that responsibility through its sponsorship of the Regeneron Science Talent Search.
Lodo Therapeutics, based in New York, formed a strategic drug discovery collaboration with Genentech, a Roche company, in a deal potentially worth more than $1 billion.
It has been noted that a number of billionaires—at least six—who are fifty years or older in age, have been investing in health care and longevity-related startup companies.
Sitting before a Congressional panel Tuesday the heads of pharmaceutical distributing companies said their mea culpas over not doing more to limit the flow of prescription opioids to certain parts of the country.
Pharmaceutical execs who leave their positions with big pharmaceutical companies, unless opting to retire for good, often move to leadership positions at other big companies. There are other choices.
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
The Information Technology & Innovation Foundation recently published a report diving into the U.S.’s trade deficits in the life sciences industry worldwide and steps that can be made to keep the biopharma and medical device industries competitive globally.
Failed blood-testing developer Theranos was known for its high-profile supporters who had tremendous business and political clout. Names like Rupert Murdoch, Betsy Devos and James Baker were known investors in the company.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
PRESS RELEASES